---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001755"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:47:03.093820+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alnylam reports preliminary 2025 net product revs $2,987M (+81% YoY); guides 2026 revs $4.9B-$5.3B

## Summary
- Preliminary 2025 net product revenue $2,987M (81% growth vs 2024); TTR franchise $2,487M (103% growth).
- 2026 combined net product revenue guidance $4.9B–$5.3B (71% growth at midpoint); TTR guidance $4.4B–$4.7B.
- New 'Alnylam 2030' strategy targets 25%+ total revenue CAGR and ~30% non-GAAP operating margin by 2030.
- Pipeline goals: nucresiran Phase 3 in ATTR-CM/polyneuropathy; mivelsiran Phase 2 enrollment in H1 2026.
- Preliminary Q4 2025: total TTR revs ~$859M (AMVUTTRA $827M, ONPATTRO $32M); total rare revs ~$137M.

## SEC filing metadata
- accession: 0001628280-26-001755
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000162828026001755/0001628280-26-001755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000162828026001755/alny-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001755
- JSON: https://secwatch.observer/filing/0001628280-26-001755.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.